Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REATA PHARMACEUTICALS, INC.

(RETA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
96.35(c) 98.88(c) 98.36(c) 98.8(c) 97.23(c) Last
237 844 285 312 160 597 140 731 165 873 Volume
-2.12% +2.63% -0.53% +0.45% -1.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 6,63 M - -
Net income 2021 -305 M - -
Net cash position 2021 652 M - -
P/E ratio 2021 -11,6x
Yield 2021 -
Sales 2022 44,6 M - -
Net income 2022 -360 M - -
Net cash position 2022 238 M - -
P/E ratio 2022 -10,3x
Yield 2022 -
Capitalization 3 538 M 3 538 M -
EV / Sales 2021 436x
EV / Sales 2022 74,0x
Nbr of Employees 267
Free-Float 82,2%
More Financials
Company
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease.... 
More about the company
Ratings of Reata Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about REATA PHARMACEUTICALS, INC.
10/22REATA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)
AQ
10/15REATA PHARMACEUTICALS : Announces Presentations at the American Society of Nephrology Kidn..
BU
09/30REATA PHARMACEUTICALS : Reta Reaffirms Plan to Submit NDA for Omaveloxolone in Q1 Followin..
MT
09/30REATA PHARMACEUTICALS : Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Fo..
BU
09/30Reata Pharmaceuticals, Inc. Plans NDA Submission for Omaveloxolone
CI
08/27REATA PHARMACEUTICALS : Corporate Presentation
PU
08/20REATA PHARMACEUTICALS : Amendments to License Agreements (Form 8-K)
PU
08/20REATA PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata..
PR
08/10AFTER HOURS WATCH LIST SCORECARD : Orgo, halo, reta,
MT
08/10SECTOR UPDATE : Health Care Stocks Fade Late, Finish in the Red
MT
08/10SECTOR UPDATE : Health Care Stocks Nursing Slim Gains
MT
08/09MT NEWSWIRES AFTER HOURS WATCH LIST : Orgo, halo, reta
MT
08/09REATA PHARMACEUTICALS : Pharma Q2 Loss Widens Amid Lower Revenue, Reaffirms Cash Runway Gu..
MT
08/09REATA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
More news
News in other languages on REATA PHARMACEUTICALS, INC.
07/12IRW-PRESS : WPD Pharmaceuticals Inc.: Der Lizenzgeber von WPD Pharmaceuticals erhält FDA-F..
06/28IRW-PRESS : WPD Pharmaceuticals Inc.: WPD Pharmaceuticals plant Beginn von Phase Ib/II-Stu..
04/27IRW-PRESS : WPD Pharmaceuticals Inc.: WPD Pharmaceuticals nimmt am 10. Kongress der Polnis..
02/24IRW-PRESS : WPD Pharmaceuticals Inc.: WPD Pharmaceuticals kündigt Liefervereinbarung zu Be..
02/18IRW-PRESS : WPD Pharmaceuticals Inc.: WPD & CNS Pharmaceuticals: Positives Gutachten der P..
More news
Analyst Recommendations on REATA PHARMACEUTICALS, INC.
More recommendations
Chart REATA PHARMACEUTICALS, INC.
Duration : Period :
Reata Pharmaceuticals, Inc. Technical Analysis Chart | RETA | US75615P1030 | MarketScreener
Technical analysis trends REATA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 97,23 $
Average target price 226,44 $
Spread / Average Target 133%
EPS Revisions
Managers and Directors
J. Warren Huff Chairman, President & Chief Executive Officer
Manmeet Singh Soni Executive VP, Chief Operating & Financial Officer
W. Christian Wigley Chief Scientific Officer, SVP & Founding Scientist
Colin J. Meyer Chief Research & Development Officer, Executive VP
Edmund Doherty Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
REATA PHARMACEUTICALS, INC.-21.35%3 538
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610